

Simlandi® (adalimumab-ryvk) - New biosimilar launch

- On May 20, 2024, <u>Alvotech</u> and <u>Teva launched</u> <u>Simlandi (adalimumab-ryvk)</u>, an *interchangeable* biosimilar to AbbVie's Humira[®] (adalimumab).
 - Simlandi is available as a 40 mg/0.4 mL single-dose autoinjector.
- The <u>FDA approved</u> Simlandi in February 2024 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis (UC), plaque psoriasis, hidradenitis suppurativa (HS) and uveitis.
- Humira is also approved for the treatment for UC in pediatric patients 5 years and older, HS in 12 years of age and older, and uveitis in 2 years of age and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.